Stock Track | Rhythm Pharmaceuticals Soars 5.58% in Pre-market on Q2 Earnings Beat and Positive Phase 2 RM-718 Data

Stock Track

Aug 04

Rhythm Pharmaceuticals Inc. (RYTM) stock surged 5.58% in pre-market trading on Tuesday, driven by a combination of better-than-expected second-quarter financial results and encouraging preliminary data from a Phase 2 trial of its RM-718 therapy.

The company reported a Q2 loss of $(0.73) per share, beating the analyst consensus estimate of $(0.82) by 10.98%. Quarterly product revenue reached $71.255 million, exceeding the $67.277 million estimate and marking a 46.91% increase from the same period last year. The net loss was also narrower than IBES estimates.

In parallel, Rhythm announced preliminary Phase 2 data showing that RM-718 demonstrated a positive efficacy signal in acquired hypothalamic obesity, with a mean BMI reduction of 11.6% at week 16. The treatment was generally well tolerated, with the most common adverse events being injection site reactions, nausea, and vomiting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1165687461"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165687461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165687461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165687461","market":"nz","top_or_hot":-1,"title":"Stock Track | Rhythm Pharmaceuticals Soars 5.58% in Pre-market on Q2 Earnings Beat and Positive Phase 2 RM-718 Data","media":"Stock Track","content":"<p>Rhythm Pharmaceuticals Inc. (RYTM) stock surged 5.58% in pre-market trading on Tuesday, driven by a combination of better-than-expected second-quarter financial results and encouraging preliminary data from a Phase 2 trial of its RM-718 therapy.</p>\n<p>The company reported a Q2 loss of $(0.73) per share, beating the analyst consensus estimate of $(0.82) by 10.98%. Quarterly product revenue reached $71.255 million, exceeding the $67.277 million estimate and marking a 46.91% increase from the same period last year. The net loss was also narrower than IBES estimates.</p>\n<p>In parallel, Rhythm announced preliminary Phase 2 data showing that RM-718 demonstrated a positive efficacy signal in acquired hypothalamic obesity, with a mean BMI reduction of 11.6% at week 16. The treatment was generally well tolerated, with the most common adverse events being injection site reactions, nausea, and vomiting.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Rhythm Pharmaceuticals Soars 5.58% in Pre-market on Q2 Earnings Beat and Positive Phase 2 RM-718 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Rhythm Pharmaceuticals Soars 5.58% in Pre-market on Q2 Earnings Beat and Positive Phase 2 RM-718 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-04 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Rhythm Pharmaceuticals Inc. (RYTM) stock surged 5.58% in pre-market trading on Tuesday, driven by a combination of better-than-expected second-quarter financial results and encouraging preliminary data from a Phase 2 trial of its RM-718 therapy.</p>\n<p>The company reported a Q2 loss of $(0.73) per share, beating the analyst consensus estimate of $(0.82) by 10.98%. Quarterly product revenue reached $71.255 million, exceeding the $67.277 million estimate and marking a 46.91% increase from the same period last year. The net loss was also narrower than IBES estimates.</p>\n<p>In parallel, Rhythm announced preliminary Phase 2 data showing that RM-718 demonstrated a positive efficacy signal in acquired hypothalamic obesity, with a mean BMI reduction of 11.6% at week 16. The treatment was generally well tolerated, with the most common adverse events being injection site reactions, nausea, and vomiting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1165687461","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165687461","pubTimestamp":1785841830,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Rhythm Pharmaceuticals Inc. (RYTM) stock surged 5.58% in pre-market trading on Tuesday, driven by a combination of better-than-expected second-quarter financial results and encouraging preliminary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"股票跟踪 | Rhythm Pharmaceuticals 因第二季度盈利超出预期和第二阶段 RM-718 数据积极，盘前股价飙升 5.58%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1},"content_text":"Rhythm Pharmaceuticals Inc. (RYTM) stock surged 5.58% in pre-market trading on Tuesday, driven by a combination of better-than-expected second-quarter financial results and encouraging preliminary data from a Phase 2 trial of its RM-718 therapy.\nThe company reported a Q2 loss of $(0.73) per share, beating the analyst consensus estimate of $(0.82) by 10.98%. Quarterly product revenue reached $71.255 million, exceeding the $67.277 million estimate and marking a 46.91% increase from the same period last year. The net loss was also narrower than IBES estimates.\nIn parallel, Rhythm announced preliminary Phase 2 data showing that RM-718 demonstrated a positive efficacy signal in acquired hypothalamic obesity, with a mean BMI reduction of 11.6% at week 16. The treatment was generally well tolerated, with the most common adverse events being injection site reactions, nausea, and vomiting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}